AUTHOR=Sadeghi Poor Ranjbar Fatemeh , Mohammadyari Fatemeh , Omidvar Atharzahra , Nikzad Farhad , Doozandeh Nargesi Nooria , Varmazyar Majid , Dehghankar Soroush , Vosoughian Fatemeh , Olangian-Tehrani Sepehr , Nanbakhsh Sepehr , Mansourian Tina , Deravi Niloofar , Tutunchian Zohreh , Salahi Mehrnaz , Poudineh Mohadeseh , Ghayyem Hani 

TITLE=Zingiber officinale (Ginger) as a treatment for inflammatory bowel disease: A review of current literature

JOURNAL=Frontiers in Drug Discovery

VOLUME=Volume 2 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2022.1043617

DOI=10.3389/fddsv.2022.1043617

ISSN=2674-0338

ABSTRACT=Inflammatory bowel disease (IBD) is a catch-all name for a variety of conditions involving persistent inflammation of the digestive system. Ulcerative colitis (UC) and Crohn's disease (CD) are examples of IBD. Amino salicylates, glucocorticoids, immunosuppressants, antibiotics, and surgery in some cases, have been used for the treatment of IBD, but the short and long-term disabling adverse effects for example nausea, pancreatitis, elevated liver enzymes, allergic reactions, and other life-threatening complications remain a major clinical problem. On the other hand, herbal medicine, believed to be safer, cheaper and easily available has gained popularity for the treatment of IBD. Ginger, the Rizhome of Zingiber Officinale from the Zingiberaceae family, one of the most commonly used fresh spices and herbs, has been proposed as a potential option for IBD treatment. This review aims to summarize the data on the yin and yang of ginger use in IBD treatment.